ATH434
AssetAlso PBT434
Chelates and redistributes labile iron to prevent iron-mediated alpha-synuclein aggregation and oxidative damage.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Oxidative stress and ROS signalling
- 2
- Indications
- 2
- Trials
- 1
- Developer
Indications
2Parkinson's disease
Phase 3, longevity.technology, 6 Oct 2026
Multiple system atrophy
Phase 2, Completed, NCT05109091, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials2
- Evidence for its targets2
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.